Log in to search using one of your social media accounts:

 

Noninvasive spinal stimulation method enables paralyzed people to regain use of hands, study finds
paylessimages/iStockphotoMore than 1.2 million Americans are living with paralysis from spinal cord injuries, which results in loss of the ability to perform such tasks as opening a water bottle.The ability to perform simple daily tasks can make a big difference in people ’s lives, especially for those with spinal cord injuries. A UCLA-led team of scientists reports that six people with severe spinal cord injuries — three of them completely paralyzed — have regained use of their hands and fingers for the first time in years after undergoing a nonsurgical, nonin vasive spinal stimulation procedure the rese...
Source: UCLA Newsroom: Health Sciences - April 25, 2018 Category: Universities & Medical Training Source Type: news

Surgery recovery program slashes opioid use, benefits patients, cuts costs, study finds
(University of Virginia Health System) A special recovery program for thoracic surgery patients developed at the University of Virginia Health System is getting patients home sooner while decreasing both healthcare costs and opioid use, a review of the first year of the program shows. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 24, 2018 Category: International Medicine & Public Health Source Type: news

Pleurectomy and Decortication the ‘ Way to Go ’ for Mesothelioma
Dr. Pietro Bertoglio and his colleagues at the University Hospital of Pisa stopped performing the aggressive extrapleural pneumonectomy (EPP) surgery for mesothelioma more than a decade ago. They believe it’s long overdue for everyone else to do the same and instead use the less-debilitating pleurectomy/decortication (P/D) procedure. The Journal of Thoracic and Cardiovascular Surgery recently published the University Hospital of Pisa’s 10-year experience using P/D and hyperthermic intrathoracic chemotherapy (HITHOC). Two editorial commentaries from thoracic surgeons in the U.S. accompanied the study from Italy,...
Source: Asbestos and Mesothelioma News - April 16, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

HeartStitch wins CE Mark for Trans-Apical Access and Closure device
HeartStitch said today it won CE Mark approval in the European Union for its suture-based Trans-Apical Access and Closure device. The Trans-Apical Access and Closure device is designed to provide percutaneous trans-apical access for structural heart procedures and closures. The system emulates surgical closure without need for open heart surgery or limited thoractomy access during left-heart structural heart defect repairs, the company said. “The CE Mark approval is another major step in the continuing process of establishing HeartStitch in the market as an innovator in the field of structural heart repair....
Source: Mass Device - April 12, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Regulatory/Compliance HeartStitch Source Type: news

HeartStitch touts tricuspid repair feasibility cases
Structural heart focused medtech company HeartStitch said today that its HeartStitch Remo Pro suture technique was used in a world first procedure to repair the tricuspid valve of two patients as part of a feasibility trial of the technique and the supporting technology. The procedures were performed by Dr. Yuri Pya at Astana, Kazakhstan’s National Research Cardiac Surgery Center, the company said. Both patients in the trial required tricuspid heart valve repair to remodel the annulus of their tricuspid valve to treat tricuspid regurgitation. Patients in the feasibility test tolerated the procedure and have been...
Source: Mass Device - April 10, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials HeartStitch Source Type: news

7 medtech stories we missed this week: April 6, 2018
[Image from unsplash.com]From CHF Solutions’s distribution deal to Guided Therapeutics’s licensing agreement, here are seven medtech stories we missed this week but throught were still worth mentioning. 1. CHF inks Spanish distribution deal CHF Solutions announced in an April 5 press release that it has signed a distribution agreement with Dimedix Surgical. The distribution agreement will allow Dimedix Surgical to distribute the CHF’s Aquadex FlexFlow System throughout Spain. The financial terms of the agreement were not disclosed. 2. J&J launches digital surgical training subscription service J&...
Source: Mass Device - April 6, 2018 Category: Medical Devices Authors: Danielle Kirsh Tags: Catheters Diagnostics Food & Drug Administration (FDA) Hospital Care Imaging Implants Regulatory/Compliance Surgical Ultrasound Urology Asahi Intecc aziyobiologics Biotronik CHF Solutions Inc. dimedixsurgical Guided Therapeut Source Type: news

Mesothelioma Clinical Trial Opens with Optimism in South Florida
Dr. Chukwuemeka Ikpeazu at the Sylvester Comprehensive Cancer Center has brought hope — where once there was none — to patients in South Florida with unresectable pleural mesothelioma. Ikpeazu is the principal investigator in the multicenter phase II clinical trial involving the much-anticipated immunotherapy drug durvalumab. Pharmaceutical giant AstraZeneca manufactures the drug under the brand name Imfinzi. “I am optimistic, very, very optimistic that this drug will be effective for these patients,” Ikpeazu told Asbestos.com. “All the data, all the earlier studies, are encouraging.” He...
Source: Asbestos and Mesothelioma News - April 4, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

CorWave wins $4m from French Innovation Challenge
CorWave said today it was awarded approximately $3.5 million from France’s Worldwide Innovation Challenge, financed by BpiFrance’s Invest for The Future Program. France-based CorWave said it received the funds to support continued development of its NovaPulse mini-invasive cardiac support pump designed to treat patients with chronic heart failure. The NovaPulse system utilizes undulating wave pumps to reproduce the operation of the human heart, the company said, and is intended to reduce complications associated with heart pumps. “Our breakthrough technology overcomes a major technological obstacle. Until...
Source: Mass Device - April 3, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiac Assist Devices Cardiovascular CorWave Source Type: news

LivaNova wins expanded CE Mark labeling for Bicarbon aortic valve
LivaNova (NSDQ:LIVN) said today it won expanded CE Mark labeling for its Bicarbon aortic heart valves, now cleared for use with low-dose anticoagulant therapy. The new approval clears low risk patients who’ve received a Bicarbon aortic valve implant to be targeted using a lower international normalized ratio measurement of blood coagulability, allowing for a lower-range level of anticoagulant medication therapy, the London-based company said. “When choosing a mechanical valve, patients look for a treatment option which lasts for life. The lower INR range approval for LivaNova Bicarbon Aortic Valves means p...
Source: Mass Device - March 29, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Regulatory/Compliance Replacement Heart Valves LivaNova Source Type: news

10 women medtech leaders you should know
There is a women’s leadership gap in the U.S., and women in medtech have been working to alleviate that problem. According to a report from the Centers for American Progress, women hold 52% of professional jobs in the U.S., but only 14.6% are CEOs, 8.1% are top earners and 4.6% are Fortune 500 CEOs. More specifically, 34.3% of all physicians and surgeons are women, and only 4% of healthcare CEOs are women. More women leaders, though, are making a difference in medtech. Keeping with the theme of Women’s History Month, we’ve highlighted some of the industry’s rising stars. From blockchain technol...
Source: Mass Device - March 23, 2018 Category: Medical Devices Authors: Danielle Kirsh Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Diabetes Diagnostics Hospital Care Imaging BioTrace Medical Evidation Health Insulet intersectent Medable MedTech Novartis Outset Medical patientory Silk Road Medical I Source Type: news

LivaNova launches Chinese Perceval trial
LivaNova (NSDQ:LIVN) said today it launched a new trial of its Perceval sutureless aortic valve implant in China as it pursues Chinese Registration of the device. The company claims that the lack of suturing allows the super-elastic Perceval valve to achieve optimal effective orifice area, resulting in “excellent hemodynamics.” LivaNova said procedures utilizing the Perceval valve result in shorter intensive care unit stays, reduced ventilation time and less blood transfusions. “We greatly look forward to the possibility of making this innovative technology, which has demonstrated excellent outcomes ...
Source: Mass Device - March 22, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Replacement Heart Valves LivaNova Source Type: news

FDA clears Edwards Lifesciences hypotension index software
Edwards Lifesciences (NYSE:EW) said today it won FDA de novo approval for its Acumen Hypotension Prediction Index software designed to address potential hypotension in surgical patients. The Irvine, Calif.-based company said it is engaging in a targeted launch of the system in the US following the approval, which clears the software as an adjunctive predictive cardiovascular indicator. “The Acumen Hypotension Prediction Index is a next-generation, predictive monitoring software that represents the future of how we can use patient data to improve healthcare. HPI improves patient care by providing intelligent deci...
Source: Mass Device - March 19, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Food & Drug Administration (FDA) Regulatory/Compliance Software / IT Edwards Lifesciences Source Type: news

Two Agents Equal as Pretreatment for Adrenal Tumor Surgery
(MedPage Today) -- Phenoxybenzamine, doxazosin OK for perioperative hemodynamic control during PCC resection (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 19, 2018 Category: Cardiology Source Type: news

This Liquid Biopsy Can Rule Out Early-Stage Lung Cancer
A new study has confirmed the accuracy of a liquid biopsy that can help rule out early-stage lung cancer. Published in the journal CHEST, the PANOPTIC clinical trial validated the Xpresys Lung 2 (XL2) test developed by Seattle-based Integrated Diagnostics. The test can detect two blood plasma proteins that are indicative of cancer in otherwise difficult-to-biopsy lung nodules measuring 8 to 30 mm. About 1.6 million pulmonary nodules are detected each year in the United States, and more than 90% of those smaller than two centimeters (around 3/4 inch) in diameter are benign, according to the Cleveland Clinic. Current detecti...
Source: MDDI - March 17, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: IVD Source Type: news

Corindus Creates Niche in Growing Robotics Market
The medtech robotics space is taking off with new entrants and new products hitting the market. Even firms that have been in the space for a while are beginning to see the effects in their earnings. Waltham, MA-based Corindus Vascular Robotics experienced growth and recently revealed it brought in about $4.2 million in revenue for the fourth quarter of 2017, topping Wall Street expectations of $4 million. During the fourth quarter of 2016, Corindus generated $0.5 million. Revenue for 2017 totaled $9.7 million compared to $2.8 million in 2016.  “Revenue in the quarter was driven primarily by CorPath GRX...
Source: MDDI - March 15, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Business Source Type: news

Medtronic and Edwards Duel in TAVR Space
A pair of studies support the long-term use of Medtronic’s CoreValve transcatheter aortic valve replacement (TAVR) system. The Dublin-based company unveiled results from both the Nordic Aortic Valve Intervention Trial (NOTION) and the CoreValve U.S. Pivotal Extreme Risk Study at the American College of Cardiology 67th Annual Scientific Session (ACC) this past weekend. NOTION is a physician-initiated trial that studied an all-comers population of 280 patients at least 70 years old. Patients in the trial were randomized to either Surgical Aortic Valve Replacement (SAVR) or TAVR procedures. Join us at the BIOM...
Source: MDDI - March 13, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news

Invuity prez & CEO Sawyer steps down, Flora in as interim | Personnel Moves – March 13, 2018
Invuity (NSDQ:IVTY) said late last week that its president and chief executive officer Philip Sawyer has resigned and will be replaced by board member Scott Flora on an interim basis. Flora has served as a member of the board since last November, and has held positions as prez, CEO and director of Omniguide. He has also held executive positions at Smith & Nephew (NYSE:SNN), including prez and GM of the orthopedics reconstruction division, GM of the trauma and clinical therapies division and senior VP of US & Europe. “Phil is a truly visionary leader who over his eight years as president an...
Source: Mass Device - March 13, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Boston Scientific CHF Solutions Inc. Endologix endospan Frequency Therapeutics Intuitive Surgical Invuity johnsonandjohnson Medtronic milestonescientific OmniGuide Physeon Precision Therapeutics Inc. Rau Source Type: news

Youth-Onset Type 2 Diabetes Better After Bariatric Surgery Youth-Onset Type 2 Diabetes Better After Bariatric Surgery
Unlike medical therapies, bariatric surgery put type 2 diabetes into remission and improved cardiovascular risk factors among teens, but complication rates were higher.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 12, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Abbott Proves That Size Does Matter
Abbott churned out an impressive number of new products last year, and our 2017 Medtech Company of the Year doesn't appear to be slowing down any. This week FDA approved Abbott's new pediatric mechanical heart valve, which is the first device of its kind that is small enough to be used in newborns and infants. Learn about the latest trends in medical device R&D and product development at BIOMEDevice Boston, April 18-19, 2018. Use promo code "MDDI" for 20% off conference registration and free expo access. Previously, surgeons could only use a range of larger-sized valves to replace a pediatric heart valve, Abb...
Source: MDDI - March 8, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news

Stem Cell Vaccine Carries Potential as Mesothelioma Treatment
Researchers at the Stanford University School of Medicine believe a patient-specific stem cell vaccine could become part of mesothelioma treatment — and possibly prevention — in the future. The belief stems from their recent study that demonstrated a consistent immunologic response with genetically-altered stem cells in laboratory mice carrying particular cancer cells. “This could potentially play a role for a large group of — if not all — cancers,” Dr. Joseph Wu, director of the Stanford Cardiovascular Institute, told Asbestos.com. “We envision it potentially being used as a vacci...
Source: Asbestos and Mesothelioma News - March 6, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Reimbursement Trends for Medical Devices in Japan
In conclusion, with the regulatory review speed by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) becoming competitive with FDA for PMA devices and the time to reimbursement being about a year after regulatory clearance with 80% of U.S. list price, Japan might be the best market, after the United States, to enter as an international market for many new companies. For 510(k) devices, the speed of reimbursement will be the same, although the speed to regulatory clearance remains a challenge. How soon a U.S. manufacturer submits the regulatory submission to PMDA is still the most substantial gap in term of co...
Source: MDDI - March 6, 2018 Category: Medical Devices Authors: Keisuke Suzuki Tags: Regulatory and Compliance Source Type: news

LivaNova & #039;s Refined Focus Pushes Growth
LivaNova is reinventing itself by shedding off parts that aren’t efficient and tightly focusing on building up its cardiac surgery and neuromodulation businesses. These changes seem to be paying off for the London-based company. Earlier this week, LivaNova said sales for the fourth quarter of 2017 grew 11.5%. For the full year, LivaNova had earnings per share about $3.54, which beat consensus of $3.32. “We were very pleased to exit 2017 with strong momentum and to make the financial commitments that we laid out for you from sales to earnings, LivaNova CEO Damien McDonald said, according to a transcript from See...
Source: MDDI - March 1, 2018 Category: Medical Devices Authors: Omar Ford Tags: Medical Device Business Cardiovascular Source Type: news

Medtronic inks 5-year partnership with Lehigh Valley Health Network
Medtronic (NYSE:MDT) today announced a five-year strategic partnership with Lehigh Valley Health Network looking to develop value-based solutions for patients within the network. The LVHN serves a total of eight hospitals across seven counties in Northeastern Pennsylvania, Fridley, Minn.-based Medtronic said. The healthcare network’s partnership with Medtronic will aim to create programs for more than 70 major medical conditions with goals of reducing cost by $100 million and improving outcomes for as many as 500,000 patients. “This agreement is exciting not only for Medtronic and LVHN, but also for the he...
Source: Mass Device - February 28, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Hospital Care Medtronic Source Type: news

AtriCure beats the Street during Q4, analysts predict ‘ growth acceleration ’
AtriCure (Nasdaq: ATRC) — an innovator in treatments for atrial fibrillation and left atrial appendage management — is enjoying a rise in its stock value today after releasing results that beat the Street. Mason, Ohio–based AtriCure’s stock was up 67 cents per share, or 3.7%, closing at $18.99. The company reported yesterday evening that it revenue for the quarter ended Dec. 31 was up nearly 12% year-over-year, to $46.1 million. Analyst polled by Yahoo! Finance had predicted $45.4 million in revenue. Analysts Danielle Antalffy and Rebecca Wang at Leerink suspect Atricure&rsq...
Source: Mass Device - February 27, 2018 Category: Medical Devices Authors: Chris Newmarker Tags: Business/Financial News Cardiovascular Surgical Wall Street Beat AtriCure Inc. Source Type: news

NaviGate touts implantation for Gate transcath tricuspid valve replacement
NaviGate Cardiac Structures Inc. said today that earlier this month, its catheter-guided Gate valved-stent bioprosthesis became the first orthotopic valve replacement in Canada to treat severe tricuspid regurgitation. The implantation was done at the Quebec Heart and Lung Institute, lead by interventional cardiologists Dr. Josep Rodes-Cabau and Dr. Francois Dagenais. The 79-year-old male patient who received the implant had severe symptomatic tricuspid regurgitation and was not eligible for standard cardiac surgery, according to NaviGate. “The NaviGate bioprosthesis is the only transcatheter device in development tha...
Source: Mass Device - February 22, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Replacement Heart Valves NaviGate Cardiac Structures Inc Source Type: news

B. Braun ’ s Aesculap closes $17m Dextera Surgical bankruptcy buyout
Surgical instrument maker Dextera Surgical and B. Braun subsidiary Aesculap said yesterday that they closed the $17.3 million deal to buy Dextera out of Chapter 11 bankruptcy. Redwood City, Calif.- based Dextera, formerly known as Cardica, agreed to the buyout in December 2017. The consummation Feb. 20 saw Dextera receive $13.6 million; another $2 million went into two-year escrow, $900,000 went to repay a loan from Aesculap and the balance was used to pay off contracts and leases and to settle closing expenses, according to a regulatory filing. Aesculap said it plans to oversee oper...
Source: Mass Device - February 22, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Surgical Wall Street Beat aesculap B. Braun Bankruptcy dextera Source Type: news

Paragonix Tech wins CE Mark for heart transport devices
Paragonix Technologies said today it won CE Mark approval in the European Union for its SherpaPak and SherpaPerfusion cardiac transport systems. The SherpaPak system consists of a single-use, disposable device designed for the hypothermic static preservation and transportation of the donor hearts, while the SherpaPerfusion system is a single-use, disposable device designed for hypothermic oxygenated perfusion preservation and transport of donor hearts. “Having followed the extensive research and product development activities at Paragonix Technologies over the past few years, I am impressed by the intuitive designs o...
Source: Mass Device - February 21, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Regulatory/Compliance Surgical Transplants Paragonix Technologies Source Type: news

J & amp;J Acquisition Could Give Stryker a Run for Its Money in Robotics
Johnson & Johnson is taking a deeper dive into the surgical robotics market through its latest acquisition. The New Brunswick, NJ-based company, through its French affiliate Apsis, will pick up Orthotaxy, a privately held developer of software-enabled surgical technologies, including a differentiated robotic-assisted surgery solution, for an undisclosed sum. J&J said the technology is currently in early-stage development for total and partial knee replacement, and the company plans to broaden its application for a range of orthopedic surgery procedures. Network with your colleagues in medtech at ADM ...
Source: MDDI - February 20, 2018 Category: Medical Devices Authors: Omar Ford Tags: Medical Device Business Source Type: news

Edwards Adds Bold New Chapter to TAVR Story
Edwards Lifesciences just might have leaped-frogged over some of its competitors in the burgeoning  TAVR market. The undisputed TAVR pioneer has received CE mark for its Centera valve to treat severe, symptomatic aortic stenosis patients at high risk of open-heart surgery. The Edwards Centera valve is repositionable and retrievable and can be delivered through a low-profile, 14-French, motorized delivery system. The company said the device is packaged with the valve fully pre-attached to the delivery system, which helps with simple and rapid device preparation. Network with your colleagues in medtech at ADM&...
Source: MDDI - February 15, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Medical Device Business Source Type: news

Edwards Lifesciences wins CE Mark for Centera TAVR
Edwards Lifesciences (NYSE:EW) said today it won CE Mark approval in the European Union for its self-expanding transcatheter Centera aortic heart valve, with indications for treating symptomatic aortic stenosis patients at high risk of open-heart surgery. The Centera valve is designed to be repositionable and retrievable, and is delivered through the use of a 14 French motorized delivery system in which the valve is pre-attached to the mechanism for quick preparation, the Irvine, Calif.-based company said. “With the Edwards Centera valve, European clinicians and their patients may now benefit from a self-ex...
Source: Mass Device - February 15, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Regulatory/Compliance Replacement Heart Valves Edwards Lifesciences Source Type: news

LivaNova Pumps Up its Heart Portfolio with TandemLife Deal
London-based LivaNova has been cutting deals left and right lately in an effort to focus on its areas of strength, such as cardiac surgery and neuromodulation. That's the reason the company gave last year for shedding its cardiac rhythm management business, and then for acquiring ImThera Medical.  Now the company has its sights on Pittsburgh, PA-based TandemLife. Don't miss the Advanced Design and Manufacturing Conference and Expo, March 7-8, 2018, in Cleveland, OH. LivaNova has agreed to pay $200 million upfront and up to $50 million more once certain regulatory milestones have been met.  TandemLife's advan...
Source: MDDI - February 15, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Medical Device Business Cardiovascular Source Type: news

LivaNova to buy TandemLife in deal worth up to $250m
LivaNova (NSDQ:LIVN) said today it inked a deal to acquire cardiopulmonary temporary support sollutions dev TandemLife in a deal worth up to $250 million. LivaNova said it will pay up to $250 million for TandemLife, with a total of $200 million in upfront costs and up to $50 million in contingent considerations based on regulatory milestones. London-based LivaNova said the buy is expected to be moderately accretive this year, with an expected closure date in the first half of this year. “The TandemLife systems allow hospitals to offer a comprehensive platform, which controls costs without sacrificing qualit...
Source: Mass Device - February 14, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiovascular Mergers & Acquisitions LivaNova Source Type: news

Cardiovascular Systems launches Diamondback 360 EL in the US, touts 1st patients treated
Cardiovascular Systems (NSDQ:CSII) said today it launched its FDA-cleared extended length Diamondback 360 peripheral orbital atherectomy device in the US and that the first commercial patients have been treated with the device. The first procedures were performed at the Detroit Medical Center Heart Hospital by Dr. Mahir Elder and at the Arkansas Heart Hospital by Dr. Ian Cawich and Dr. Vasili Lendel, the St. Paul, Minn.-based company said. “From a physician’s perspective, radial access is a viable alternative that allows us to minimize bleeding and avoid commonly diseased femoral arteries. Additionall...
Source: Mass Device - February 14, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Vascular Cardiovascular Systems Inc. Source Type: news

Abiomed wins expanded Impella FDA nod for elective, urgent high-risk PCI
Abiomed (NSDQ:ABMD) said today it won expanded FDA premarket approval for its Impella 2.5 and Impella CP heart pumps, now cleared for use during elective and urgent high risk percutaneous coronary intervention procedures. With the expansion, the Impella heart pump is cleared for use with patients with severe coronary artery disease, complex anatomy and a number of co-morbidities with or without depressed ejection fractions, the Danvers, Mass.-based company said. “This expanded FDA approval with moderately reduced ejection fraction validates our real-world experience using hemodynamic support in patients turned d...
Source: Mass Device - February 14, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiovascular Catheters Food & Drug Administration (FDA) Regulatory/Compliance Abiomed Source Type: news

Bariatric Surgery Enabled Stopping Diabetes Meds (CME/CE)
(MedPage Today) -- In French study, nearly half of obese patients with diabetes discontinued medications after surgery (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 14, 2018 Category: Cardiology Source Type: news

Only U.S. Cryotherapy Trial for Mesothelioma Finds Success
Thoracic surgeon Dr. Shanda Blackmon at the Mayo Clinic in Rochester, Minnesota, believes there is a place for cryotherapy in the future multidisciplinary treatment of pleural mesothelioma. She wants to show it with this groundbreaking clinical trial. “We think [cryotherapy] could play an important role in treatment,” Blackmon told Asbestos.com. “So far, things look promising, but you can’t say anything specific without more numbers. Right now, it’s a little like telling a story.” Cryotherapy involves destroying cancer cells, or any abnormal tissues, by freezing them with controlled nitr...
Source: Asbestos and Mesothelioma News - February 14, 2018 Category: Environmental Health Authors: Daniel King Tags: ADI-PEG 20 cryoablation cryotherapy intrapleural measles virus Mayo Clinic mesothelioma clinical trial Opdivo pacific mesothelioma center pleural mesothelioma pleuroscopy Shanda Blackmon Surgery for Mesothelioma After Radiation Thera Source Type: news

Prophylactic LAA Closure for Stroke Prevention in AF: Is it Really As Good An Idea As We Thought?
Results of the largest study to assess impact of left atrial appendage closure during routine non-AF-related cardiac surgery raise a few new questions.   (Source: ConsultantLive)
Source: ConsultantLive - February 13, 2018 Category: Internal Medicine Authors: Payal Kohli, MD Tags: Atrial Fibrillation Cardiovascular Diseases Source Type: news

Slow Medicine: Omega-3s, Zoster Vaccination, and Bariatric Surgery
(MedPage Today) -- Thoughtful review of hot-button topics in the news (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 9, 2018 Category: Cardiology Source Type: news

Metabolic Surgery Prevents T2D Microvascular Complications
(MedPage Today) -- Approach improved pre-existing diabetic nephropathy versus medical treatment (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 7, 2018 Category: Cardiology Source Type: news

Nigeria:Nigerian Experts Worry Over Lack of Access to Treatment of Heart Diseases
[Vanguard] Surgeons in the field of cardiovascular and thoracic medicine have raised the alarm over poor access to treatment and services in Nigeria, lamenting that only 2 per cent have access to treatment abroad while 98 percent stay at home and die. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 7, 2018 Category: African Health Source Type: news

Malaysia ’s IHH, Temasek eye majority stake in Medanta
IHH Healthcare, the world ’s second-largest hospital chain by market value, is keen on becoming a strategic partner to Trehan, a well-known cardiovascular surgeon turned medical entrepreneur, who will retain significant minority ownership. (Source: The Economic Times)
Source: The Economic Times - February 6, 2018 Category: Consumer Health News Source Type: news

‘This Is Us’ Finally Revealed How Jack Pearson Died. Here’s What a Doctor Says You Should Know About the Condition
Spoiler alert: Last night on the hit TV show This Is Us, viewers finally learned how one of the main characters, Jack Pearson, dies. After waking in the middle of the night to a fire in his home, the father of three helped his wife and children escape, rescued the family pet and managed to retrieve important family heirlooms from the burning building. But later, at the hospital, Jack went into cardiac arrest as a result of smoke inhalation. “It was catastrophic, and I’m afraid we’ve lost him,” a doctor told Jack’s wife, Rebecca. When relaying Jack’s death to his best friend Miguel, Rebec...
Source: TIME: Health - February 5, 2018 Category: Consumer Health News Authors: Amanda MacMillan Tags: Uncategorized healthytime medicine onetime Source Type: news

' Striking' Survival Benefit With Surgery for Esophageal Cancer'Striking' Survival Benefit With Surgery for Esophageal Cancer
Patients with esophageal cancer who opt out of surgery when it is recommended may not live as long as their peers who have surgery, according to research presented January 30 at the Society of Thoracic Surgeons annual meeting.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 2, 2018 Category: Surgery Tags: Hematology-Oncology News Source Type: news

LivaNova wins CE Mark for PureFlex arterial cannulae
LivaNova (NSDQ:LIVN) said yesterday it won CE Mark approval in the European Union for its PureFlex line of adult arterial cannulae. The newly cleared PureFlex cannulae are designed with curved and straight tip options and feature phthalate-free flexible tubing and a wire-reinforcement spring, the London-based company said. “Our decades-long commitment to excellence in cannulation continues with the addition of the new PureFlex cannulae to our robust portfolio. We call it ‘the cannulae that can. Now with CE Mark, we are eager to offer this high-quality line of cannulae to cardiac surgery teams and skilled s...
Source: Mass Device - February 2, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Regulatory/Compliance LivaNova Source Type: news

Zurich ’s Air Medical Program Flies Seven ECMO Missions in Ten Days
In a ten day period in January, Rega aircraft in Zurich, Switzerland transported and cared for a total of seven patients, including a two-year-old child, with the most severe cardiovascular and pulmonary disease. This was made possible by a small, portable heart-lung extracorporeal membrane oxygenation (ECMO) machine, which is compatible with both the ambulance jets, and the two types of helicopters used by Rega. Since 2009, Rega has been the only air rescue organization in Switzerland to have its own ECMO equipment. The devices have been instrumental in the care and transport of 25 intensive care patients annually. That&r...
Source: JEMS Patient Care - February 1, 2018 Category: Emergency Medicine Authors: A.J. Heightman, MPA, EMT P Tags: Cardiac & Resuscitation Patient Care Operations Source Type: news

Zurich ’s Air Medical Program Flies Seven ECMO Missions in Ten Days
In a ten day period in January, Rega aircraft in Zurich, Switzerland transported and cared for a total of seven patients, including a two-year-old child, with the most severe cardiovascular and pulmonary disease. This was made possible by a small, portable heart-lung extracorporeal membrane oxygenation (ECMO) machine, which is compatible with both the ambulance jets, and the two types of helicopters used by Rega. Since 2009, Rega has been the only air rescue organization in Switzerland to have its own ECMO equipment. The devices have been instrumental in the care and transport of 25 intensive care patients annually. That&r...
Source: JEMS Operations - February 1, 2018 Category: Emergency Medicine Authors: A.J. Heightman, MPA, EMT P Tags: Cardiac & Resuscitation Patient Care Operations Source Type: news

Study: Talc Pleurodesis a Viable Option for Mesothelioma
Some patients with mesothelioma should consider the less-invasive talc pleurodesis procedure instead of aggressive, tumor-removing surgery, based on recent research from doctors at Mount Sinai Hospital. Although talc pleurodesis is considered only palliative, survival time often is not significantly different between the two procedures, according to the study published by Journal of Thoracic Disease. “There should be comprehensive conversation with your physician about treatment options, not only about survival, but about quality of life,” Dr. Emanuela Taioli, department of thoracic surgery, Icahn School of Me...
Source: Asbestos and Mesothelioma News - January 29, 2018 Category: Environmental Health Authors: Daniel King Tags: Emanuela Taioli extrapleural pneumonectomy Institute for Translational Epidemiology Journal of Thoracic Disease Maaike van Gerwen mesothelioma surgery Mount Sinai Hospital pleural effusions pleural mesothelioma pleurectomy and decorticat Source Type: news

Boston Scientific Seizes an Opportunity in Mitral Valve Repair
Boston Scientific may be gearing up to make an acquisition in the mitral valve repair space sometime in the next year or two. The Marlborough, MA-based company purchased $90 million worth of stock in Millipede, a Santa Ana, CA-based company that has developed the Iris transcatheter annuloplasty ring system for the treatment of severe mitral regurgitation (MR). The two companies also reached an agreement giving Boston Scientific the option to acquire Millipede at any time prior to the completion of a first-in-human study that meets certain parameters. After the study, Millipede has the option to compel Boston Scientific to ...
Source: MDDI - January 24, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Medical Device Business Source Type: news

Thromboembolism Less Likely With LAA Closure Added to Cardiac Surgery
(MedPage Today) -- Concomitant procedure tied to fewer events, registry data shows (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 23, 2018 Category: Cardiology Source Type: news